MedTrace Logo

Eluxadoline Bile Acid Malabsorption (BAM) Study

NCT03441581 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-05-19

Study results available
· View outcomes & findings →

Summary

This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG

Eluxadoline

Eluxadoline 100 mg oral tablets BID with food.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Anna Muslin · Allergan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2020-04-28
Completion
2020-04-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03441581 on ClinicalTrials.gov